IAM
AXSM icon

Innovis Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Innovis Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$365K Hold
5,221
– – 0.14% 83
2023
Q2 		$375K Sell
5,221
-5,433
-51% -$401K 0.14% 94
2023
Q1 		$657K Buy
10,654
+3,441
+48% +$226K 0.27% 65
2022
Q4 		$556K Buy
+7,213
New +$431K 0.25% 70

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Innovis Asset Management's AXSM Position: Q3 2023 in Review

Innovis Asset Management held its Axsome Therapeutics (AXSM) position steady in Q3 2023 at 5,221 shares worth $365K. The position accounts for 0.14% of the portfolio, ranked #83.

Innovis Asset Management first reported a position in AXSM in Q4 2022 and has held it in 4 quarters since. The position peaked at $657K in Q1 2023. 226 funds tracked by Wall St. Rank hold AXSM as of Q3 2023.

  • Innovis Asset Management held 5,221 shares of Axsome Therapeutics worth $365K as of Q3 2023.
  • Innovis Asset Management left its Axsome Therapeutics share count unchanged in Q3 2023.
  • Axsome Therapeutics made up 0.14% of Innovis Asset Management's portfolio in Q3 2023, its #83 holding.
  • Innovis Asset Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • Innovis Asset Management's Axsome Therapeutics position peaked at $657K in Q1 2023.
  • 226 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.